Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant

• Status: Active, not recruiting
• Trial end date: 2021-12-31

Summary

This phase II trial studies the side effects and how well dinutuximab and sargramostim work with combination chemotherapy in patients with high-risk neuroblastoma undergoing stem cell transplant. Immunotherapy with monoclonal antibodies, such as dinutuximab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Sargramostim helps the body produce normal infection-fighting white blood cells. Giving chemotherapy before a stem cell transplant, with drugs such as cisplatin, etoposide, vincristine, doxorubicin, cyclophosphamide, thiotepa, melphalan, etoposide, carboplatin, topotecan, and isotretinoin, helps kill any cancer cells that are in the body and helps make room in a patient's bone marrow for new blood-forming cells (stem cells). Giving dinutuximab and sargramostim with combination chemotherapy may work better than combination chemotherapy alone in treating patients with high-risk neuroblastoma undergoing stem cell transplant.

• Phase: Phase 2

Details

• Lead Sponsor: National Cancer Institute (NCI)
• Treatments: 3,6-bis(5-chloro-2-piperidyl)-2,5-piperazinedione; Aldesleukin; Antibodies; Antibodies, Monoclonal; Carboplatin; Cisplatin; Cyclophosphamide; Daunorubicin; Dexrazoxane; Dinutuximab; Doxorubicin; Etoposide; Etoposide phosphate; Interleukin-2; Isotretinoin; Liposomal doxorubicin; Mechlorethamine; Melphalan; Nitrogen Mustard Compounds; Podophyllotoxin; Razoxane; Sargramostim; Thiotepa; Topotecan; Tretinoin; Vincristine; Vitamin A